tumor necrosis factor-alpha convertase

a membrane zinc-containing endopeptidase; SPRACT is an isoform of ADAM17 corresponding to the cytoplasmic domain; RefSeq NM_009615 (Adam17, mouse); NM_003183 (ADAM17, human); NM_020306 (rat)
Also Known As:
ADAM-17; ADAM17 protein; ADAM17 protein, human; Adam17 protein, mouse; Adam17 protein, rat; SPRACT protein, human; TACA (enzyme); TACE (enzyme); TACE protein, human; TACE protein, rat; TNF-alpha converting enzyme; TNF-alpha converting enzyme, mouse; Tace protein, mouse; a disintegrin and metalloprotease domain 17 protein; a disintegrin and metalloproteinase domain 17 protein, human; a disintegrin and metalloproteinase domain 17 protein, mouse; a disintegrin and metalloproteinase domain 17 protein, rat; tumor necrosis factor alpha convertase; tumor necrosis factor, alpha, converting enzyme, human; tumor necrosis factor, alpha, converting enzyme, rat; tumor necrosis factor-alpha converting enzyme
Networked: 150 relevant articles (4 outcomes, 14 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Federici, Massimo: 4 articles (01/2010 - 12/2005)
2. Lauro, Renato: 4 articles (01/2010 - 12/2005)
3. Menghini, Rossella: 4 articles (01/2010 - 12/2005)
4. Levin, J I: 4 articles (03/2006 - 10/2001)
5. Crown, J: 3 articles (06/2015 - 06/2008)
6. McGowan, P M: 3 articles (06/2015 - 06/2008)
7. Duffy, M J: 3 articles (06/2015 - 06/2008)
8. Khokha, Rama: 3 articles (01/2010 - 12/2005)
9. Fiorentino, Loredana: 3 articles (01/2010 - 10/2007)
10. McGowan, Patricia M: 3 articles (05/2009 - 04/2007)

Related Diseases

1. Ischemia
09/01/2009 - "Preconditioning with sublethal ischemia or intermittent normobaric hyperoxia up-regulates glutamate transporters and tumor necrosis factor-alpha converting enzyme in the rat brain."
04/01/2004 - "DPH-067517 selectively inhibited TACE enzyme activity in vitro (K(i) = 2.8 nM), and effectively suppressed ischemia-induced increase in soluble TNFalpha in brain tissue after systemic administration. "
08/01/2009 - "To evaluate the anti-angiogenic efficacy of CB-12181 [an azasugar derivative that has inhibitory actions against matrix metalloproteinases (MMPs) and tumor necrosis factor-alpha (TNF-alpha) converting enzyme (TACE)], we investigated the suppressing ability on in vitro (tube formation by endothelial cells) and in vivo (retinal neovascularization on murine ischemia-induced proliferative retinopathy) models of angiogenesis. "
09/24/2007 - "Here, we assessed the effects of PKF242-484 and PKF241-466, two dual inhibitors of TNF-alpha converting enzyme (TACE) and matrix metalloproteinases (MMPs), in a model of ischemia and reperfusion injury in mice. "
12/01/2008 - "In isolated ventilated (by air containing 5% CO(2)) rat lungs, in which differential perfusion of the RL or LL was feasible, the LL was selectively made ischemic (60 min) and reperfused (30 min) in a nonrecirculating or recirculating manner with buffer (Krebs-Henseleit) solution, or in a recirculating manner with buffer that contained apocynin (10 mmol/L) or apocynin + TACEI (tumor necrosis factor)-alpha converting enzyme inhibitor; 10 microg/mL) (each group: n = 12) or with buffer that contained SOD (superoxide dismutase, 3000 U before ischemia and at reperfusion) or SOD + TACEI (each group: n = 5). "
2. Reperfusion Injury
3. Polycystic Kidney Diseases (Polycystic Kidney Disease)
4. Retinal Neovascularization
5. Kidney Diseases (Kidney Disease)

Related Drugs and Biologics

1. Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
2. Tissue Inhibitor of Metalloproteinase-3
3. Matrix Metalloproteinases
4. 3,4,5- trihydroxy- 1- (4'- phenoxybenzenesulfonyl)piperidine- 2- hydroxy amide
5. hydroxide ion
6. tumor necrosis factor-alpha convertase
7. Messenger RNA (mRNA)
8. Transforming Growth Factor alpha (TGF-alpha)
9. Metalloproteases (Metalloproteinases)
10. Proteins (Proteins, Gene)

Related Therapies and Procedures

1. Drug Therapy (Chemotherapy)